Actionable biomarker-informed treatment decisions rely on the acquisition of quality tissue samples1-4
- Sufficient amounts of quality tumor specimens enable identification of actionable determination of biomarkers5
- Careful, proactive management of tissue is critical in order to maximize its availability for downstream testing5
- Testing at initial diagnosis can help optimize the use of precious tissue and decrease time to delivery of targeted therapy options5,6